Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of JNJ-64991524 in Healthy Participants
NCT03346122Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-64991524 (10 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Treatment Emergent Adverse Events and Number of Participants with Abnormalities in Vital Signs, Physical Examinations, Electrocardiogram (ECG), Cardiac Telemetry and Clinically Significant Laboratory Findings. Started Nov 2017; status: completed.
02
Drugs
JNJ-64991524
Beyond the preview
Go deeper on NCT03346122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346122.